1887

Abstract

The complement alternative pathway (AP) is tightly regulated and changes in two important AP components, factor B (FB) and factor H (FH) are linked to severe dengue in humans. Here, a mouse model of dengue was investigated to define the changes in FB and FH and assess the utility of this model to study the role of the AP in severe dengue. Throughout the period of viremia in the AG129 IFN signalling-deficient mouse, an increase in FB and a decrease in FH was observed following dengue virus (DENV) infection, with the former only seen in a model of more severe disease associated with antibody-dependent enhancement (ADE). Terminal disease was associated with a decrease in FB and FH, with greater changes during ADE, and accompanied by increased C3 degradation consistent with complement activation. analysis of NFκΒ, signal transducer and activator of transcription (STAT) and IFN-driven FB and FH promoter elements to reflect the likely impact of the lack of IFN-responses in AG129 mice, demonstrated that these elements differed markedly between human and mouse, notably with mouse FH lacking NFκΒ and key IFN-stimulated response elements (ISRE), and FB with many more NFκΒ and STAT-responsive elements than human FB. Thus, the AG129 mouse offers utility in demonstrating changes in FB and FH that, similar to humans, are associated with severe disease, but lack predicted important human-specific and IFN-dependent responses of FB and FH to DENV-infection that are likely to regulate the subtleties of the overall AP response during dengue disease in humans.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001547
2021-01-07
2021-08-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/102/3/vir001547.html?itemId=/content/journal/jgv/10.1099/jgv.0.001547&mimeType=html&fmt=ahah

References

  1. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480–496 [View Article][PubMed]
    [Google Scholar]
  2. Sabin AB. The dengue group of viruses and its family relationships. Bacteriol Rev 1950; 14:225–232[PubMed]
    [Google Scholar]
  3. WHO Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, New Edition. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; 2009
    [Google Scholar]
  4. Halstead SB. Dengue. Lancet 2007; 370:1644–1652 [View Article][PubMed]
    [Google Scholar]
  5. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265:739–741 [View Article][PubMed]
    [Google Scholar]
  6. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2–9 [View Article][PubMed]
    [Google Scholar]
  7. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421–467 [View Article][PubMed]
    [Google Scholar]
  8. Carr JM, Hocking H, Bunting K, Wright PJ, Davidson A et al. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J Med Virol 2003; 69:521–528 [View Article][PubMed]
    [Google Scholar]
  9. Chen Y-C, Wang S-Y. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 2002; 76:9877–9887 [View Article][PubMed]
    [Google Scholar]
  10. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med 2015; 7:304ra141 [View Article][PubMed]
    [Google Scholar]
  11. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 2015; 7:304ra142 [View Article][PubMed]
    [Google Scholar]
  12. Nascimento EJM, Hottz ED, Garcia-Bates TM, Bozza F, Marques ETA et al. Emerging concepts in dengue pathogenesis: interplay between plasmablasts, platelets, and complement in triggering vasculopathy. Crit Rev Immunol 2014; 34:227–240 [View Article][PubMed]
    [Google Scholar]
  13. Nascimento EJM, Silva AM, Cordeiro MT, Brito CA, Gil LHVG et al. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One 2009; 4:e6782 [View Article][PubMed]
    [Google Scholar]
  14. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system Part I - molecular mechanisms of activation and regulation. Front Immunol 2015; 6:262 [View Article][PubMed]
    [Google Scholar]
  15. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system Part II: role in immunity. Front Immunol 2015; 6:257 [View Article][PubMed]
    [Google Scholar]
  16. Kemper C, Pangburn MK, Fishelson Z. Complement nomenclature 2014. Mol Immunol 2014; 61:56–58 [View Article][PubMed]
    [Google Scholar]
  17. Walport MJ. Complement. first of two parts. N Engl J Med 2001; 344:1058–1066 [View Article][PubMed]
    [Google Scholar]
  18. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785–797 [View Article][PubMed]
    [Google Scholar]
  19. Milder FJ, Gomes L, Schouten A, Janssen BJC, Huizinga EG et al. Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol 2007; 14:224–228 [View Article][PubMed]
    [Google Scholar]
  20. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 1976; 73:3268–3272 [View Article][PubMed]
    [Google Scholar]
  21. Bokisch VA, Top FH, Russell PK, Müller-Eberhard HJ, Müller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973; 289:996–1000 [View Article][PubMed]
    [Google Scholar]
  22. Churdboonchart V, Bhamarapravati N, Futrakul P. Crossed immunoelectrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. observations in patients' plasma. Am J Trop Med Hyg 1983; 32:569–576 [View Article][PubMed]
    [Google Scholar]
  23. Zhang K, Lu Y, Harley KT, Tran M-H. Atypical hemolytic uremic syndrome: a brief review. Hematol Rep 2017; 9:7053 [View Article][PubMed]
    [Google Scholar]
  24. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8:634–642 [View Article][PubMed]
    [Google Scholar]
  25. Avirutnan P, Hauhart RE, Marovich MA, Garred P, Atkinson JP et al. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. mBio 2011; 2: 13 12 2011 [View Article][PubMed]
    [Google Scholar]
  26. Douradinha B, McBurney SP, Soares de Melo KM, Smith AP, Krishna NK et al. C1Q binding to dengue virus decreases levels of infection and inflammatory molecules transcription in THP-1 cells. Virus Res 2014; 179:231–234 [View Article][PubMed]
    [Google Scholar]
  27. Fuchs A, Lin T-Y, Beasley DW, Stover CM, Schwaeble WJ et al. Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010; 8:186–195 [View Article][PubMed]
    [Google Scholar]
  28. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007; 2:417–426 [View Article][PubMed]
    [Google Scholar]
  29. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010; 207:793–806 [View Article][PubMed]
    [Google Scholar]
  30. Avirutnan P, Hauhart RE, Somnuke P, Blom AM, Diamond MS et al. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011; 187:424–433 [View Article][PubMed]
    [Google Scholar]
  31. Conde JN, da Silva EM, Allonso D, Coelho DR, Andrade IdaS et al. Inhibition of the membrane attack complex by dengue virus NS1 through interaction with vitronectin and terminal complement proteins. J Virol 2016; 90:9570–9581 [View Article][PubMed]
    [Google Scholar]
  32. Kurosu T, Chaichana P, Yamate M, Anantapreecha S, Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun 2007; 362:1051–1056 [View Article][PubMed]
    [Google Scholar]
  33. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 2006; 103:19111–19116 [View Article][PubMed]
    [Google Scholar]
  34. Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N et al. Complement alternative pathway genetic variation and dengue infection in the Thai population. Clin Exp Immunol 2013; 174:326–334 [View Article][PubMed]
    [Google Scholar]
  35. Cabezas S, Bracho G, Aloia AL, Adamson PJ, Bonder CS et al. Dengue virus induces increased activity of the complement alternative pathway in infected cells. J Virol 2018; 92: 15 07 2018 [View Article][PubMed]
    [Google Scholar]
  36. Quinn EJ, Cheong AH-C, Calvert JK, Higgins G, Hahesy T et al. Clinical features and laboratory findings of travelers returning to South Australia with dengue virus infection. Trop Med Infect Dis 2018; 3:6–14 [View Article][PubMed]
    [Google Scholar]
  37. Ng JKW, Zhang SL, Tan HC, Yan B, Martinez JM et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog 2014; 10:e1004031 [View Article][PubMed]
    [Google Scholar]
  38. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101–1108 [View Article][PubMed]
    [Google Scholar]
  39. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9:671–675 [View Article][PubMed]
    [Google Scholar]
  40. Quandt K, Frech K, Karas H, Wingender E, Werner T, MatInd WT. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23:4878–4884 [View Article][PubMed]
    [Google Scholar]
  41. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21:2933–2942 [View Article][PubMed]
    [Google Scholar]
  42. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004; 78:2701–2710 [View Article][PubMed]
    [Google Scholar]
  43. Tan GK, Ng JKW, Trasti SL, Schul W, Yip G et al. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010; 4:e672 [View Article][PubMed]
    [Google Scholar]
  44. Lee PX, Ong LC, Libau EA, Alonso S. Relative contribution of dengue IgG antibodies acquired during gestation or breastfeeding in mediating dengue disease enhancement and protection in type I interferon receptor-deficient mice. PLoS Negl Trop Dis 2016; 10:e0004805 [View Article][PubMed]
    [Google Scholar]
  45. Zompi S, Harris E. Animal models of dengue virus infection. Viruses 2012; 4:62–82 [View Article][PubMed]
    [Google Scholar]
  46. Williams KL, Zompi S, Beatty PR, Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009; 1171 Suppl 1:E12–23 [View Article][PubMed]
    [Google Scholar]
  47. Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S et al. The C3dg fragment of complement is superior to conventional C3 as a diagnostic biomarker in systemic lupus erythematosus. Front Immunol 2018; 9:581 [View Article][PubMed]
    [Google Scholar]
  48. Carlin AF, Plummer EM, Vizcarra EA, Sheets N, Joo Y et al. An IRF-3-, IRF-5-, and IRF-7-Independent pathway of dengue viral resistance utilizes IRF-1 to stimulate Type I and II interferon responses. Cell Rep 2017; 21:1600–1612 [View Article][PubMed]
    [Google Scholar]
  49. Li X-Q, Li XN, Liang J-J, Cai X-B, Tao Q et al. IRF1 up-regulates ISG15 gene expression in dsRNA stimulation or CSFV infection by targeting nucleotides -487 to -325 in the 5' flanking region. Mol Immunol 2018; 94:153–165 [View Article][PubMed]
    [Google Scholar]
  50. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472:481–485 [View Article][PubMed]
    [Google Scholar]
  51. Pastor AF, Rodrigues Moura L, Neto JWD, Nascimento EJM, Calzavara-Silva CE et al. Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Hum Immunol 2013; 74:1225–1230 [View Article][PubMed]
    [Google Scholar]
  52. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285:1–24 [View Article][PubMed]
    [Google Scholar]
  53. Maneekan P, Leaungwutiwong P, Misse D, Luplertlop N. T helper (th) 1 and Th2 cytokine expression profile in dengue and malaria infection using magnetic bead-based bio-plex assay. Southeast Asian J Trop Med Public Health 2013; 44:31–36[PubMed]
    [Google Scholar]
  54. Chua JJ-E, Bhuvanakantham R, Chow VT-K, Ng M-L. Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human Stat3beta protein. Virus Res 2005; 112:85–94 [View Article][PubMed]
    [Google Scholar]
  55. Chen M, Sun F, Han L, Qu Z. Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 2016; 7:33363–33373 [View Article][PubMed]
    [Google Scholar]
  56. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 2001; 283:1150–1156 [View Article][PubMed]
    [Google Scholar]
  57. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev 2001; 12:133–142 [View Article][PubMed]
    [Google Scholar]
  58. Zhang X, Zhang Z, He S, Fu Y, Chen Y et al. Foxo3, IRF4, and xIAP are correlated with immune activation in HIV-1-infected men who have sex with men during early HIV infection. AIDS Res Hum Retroviruses 2017; 33:172–180 [View Article][PubMed]
    [Google Scholar]
  59. Marié I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. Embo J 1998; 17:6660–6669 [View Article][PubMed]
    [Google Scholar]
  60. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998; 441:106–110 [View Article][PubMed]
    [Google Scholar]
  61. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM et al. Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J Virol 2012; 86:12561–12570 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001547
Loading
/content/journal/jgv/10.1099/jgv.0.001547
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error